Organon Acquired by Sun Pharma | Healthcare M&A Deal

Sun Pharma has acquired Organon, a pharmacy business in New Jersey, for $11.75 billion enterprise valuation. Sun Pharma acquisitions add Organon’s women’s health and general medicines portfolio, including biosimilars, commercialized across 140 countries, with major markets in the U.S., Europe, China, Canada, and Brazil. Organon acquisition expands healthcare M&A capabilities through a trusted brand base and a global footprint supported by manufacturing facilities. The strategic acquisition is structured as a merger acquisition in an all-cash deal valued at $14.00 per share, with Sun Pharma as a strategic buyer and the transaction announced for completion subject to customary closing conditions.